

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/554,397	09/26/2006	Yoshitake Natsume	279648US0PCT	2754	
OBLON SPIN	7590 09/30/201 YAK, MCCLELLAND	EXAM	EXAMINER		
1940 DUKE STREET			HAN, KWANG S		
ALEXANDRI	A, VA 22314	ART UNIT	PAPER NUMBER		
		1795			
			NOTIFICATION DATE	DELIVERY MODE	
			09/30/2010	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/554,397	NATSUME ET AL.		
Examiner	Art Unit		
Kwang Han	1795		

	Kwang Han	1795	
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REPLY FILED 15 September 2010 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
<ol> <li>The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following i application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:</li> </ol>	the same day as filing a Notice of eplies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
<ul> <li>a) The period for reply expiresmonths from the mailing</li> </ul>	date of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this Ar no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I	ter than SIX MONTHS from the mailing	date of the final rejection	n.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f			
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purposes of determining the period off exh under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set set for thin (b) above, if checked. Any reply re-eviet by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount hortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria nally set in the final Offic e of the final rejection, e	ate extension fee e action; or (2) as ven if timely filed,
<ol> <li>The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi</li> </ol>	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
<u>AMENDMENTS</u>			
The proposed amendment(s) filed after a final rejection, be  (a) They raise new issues that would require further cor  (b) They raise the issue of new matter (see NOTE below  (c) They are not deemed to place the application in better	sideration and/or search (see NO) w);	ΓE below);	
appeal; and/or	or form for appear by materially rec	adding of simplifying ti	16 133463 101
(d) ☐ They present additional claims without canceling a c	orresponding number of finally reje	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (I	OL-324).
5. Applicant's reply has overcome the following rejection(s):			
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>	owable if submitted in a separate, t	imely filed amendmer	it canceling the
7.  For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		l be entered and an ex	planation of
Claim(s) allowed: Claim(s) objected to:			
Claim(s) rejected: 1.3.5.7.12-14 and 19.			
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
<ol> <li>The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea	al and/or appellant fails	to provide a
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after er	ntry is below or attache	ed.
11. ☑ The request for reconsideration has been considered but	does NOT place the application in	condition for allowan	ce because:
see continuation.			
12. Note the attached Information Disclosure Statement(s). (	PTO/SB/08) Paper No(s)		
13. Other:			
/Dah-Wei D. Yuan/ Supervisory Patent Examiner, Art Unit 1795			

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Applicant argues the Hara and Yamamoto references are divergent and no motivation for combing the references exist and the comparison between examples 1-8 and conventional example 1 as shown in the specification provides evidence of unexpected results. In response to Applicant's arguments please consider the following: the Hara reference discloses the negative electrode having a thin film of silicon oxide on the surface of the collector is further modified by the teachings of Yamamoto towards a method of forming active material layer and its respective thickness. Both references are directed towards lithium ion batteries and the motivation to modify as recited in the office action is sufficient. In response to applicant's arguments against the references individually where the rejections are based on combinations of references. See In re Keller, 62F.2d 413, 208 USPG 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPG 375 (Fed. Cir. 1986). In regards to the showing crevelence tresults, as previously discussed in the final office action, the data as provided within Table 1 showns oxygen molar ratios ranging from 0.5 to 1.2 with corresponding linital efficiency per values which does not provide any data as showing unexpected results to a specific oxygen molar ration formed from various electrode formation methods since all the examples with varying oxygen molar ratio values essentially have the same initial efficiency percent and initial charge values. The comparison between the conventional example and examples 1-8 show results which are affected by the electrode formation method and the thin film thickness but no criticality in the oxygen molar ration formation.